Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination

Yael Eshet; Noam Tau; Yousef Alhoubani; Nayroz Kanana; Liran Domachevsky; Michal Eifer

doi:10.1148/radiol.2021210886

Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination

Radiology. 2021 Sep;300(3):E345-E347. doi: 10.1148/radiol.2021210886. Epub 2021 Apr 27.

Authors

Yael Eshet¹, Noam Tau¹, Yousef Alhoubani¹, Nayroz Kanana¹, Liran Domachevsky¹, Michal Eifer¹

Affiliation

¹ From the Department of Diagnostic Imaging, Chaim Sheba Medical Center, Sheba Road 2, 52621 Ramat Gan, Israel (Y.E., N.T., Y.A., N.K., L.D., M.E.); and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel (Y.E., N.T., L.D., M.E.).

Abstract

Ipsilateral avid axillary lymph node uptake at FDG PET/CT persists in 29% (49 of 169) of patients between 7 to 10 weeks after the second dose of the mRNA-based BNT162b2 COVID-19 vaccination.

Publication types

Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
Fluorodeoxyglucose F18*
Humans
Lymph Nodes / diagnostic imaging
Positron Emission Tomography Computed Tomography
Prevalence
RNA, Messenger
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines
RNA, Messenger
Fluorodeoxyglucose F18